Independent Portfolio Consultants’s United Therapeutics UTHR Stock Holding History

Independent Portfolio Consultants’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6K	Sell	45 -70	-61%	-$8.73K	﹤0.01%	760
2017 Q1	$16K	Hold	115	–	–	0.01%	685
2016 Q4	$16K	Sell	115 -50	-30%	-$6.38K	0.01%	650
2016 Q3	$19K	Sell	165 -10	-6%	-$1.2K	0.01%	631
2016 Q2	$19K	Hold	175	–	–	0.01%	646
2016 Q1	$20K	Buy	+175	New	+$22.1K	0.01%	665
2015 Q4	–	Sell	-173	Closed	-$23K	–	808
2015 Q3	$23K	Buy	173 +15	+9%	+$2.41K	0.01%	669
2015 Q2	$27K	Buy	158 +88	+126%	+$15.8K	0.01%	691
2015 Q1	$12K	Sell	70 -585	-89%	-$89.2K	﹤0.01%	717
2014 Q4	$85K	Buy	655 +70	+12%	+$9.02K	0.02%	547
2014 Q3	$75K	Hold	585	–	–	0.02%	583
2014 Q2	$52K	Buy	+585	New	+$56.3K	0.01%	637
2014 Q1	–	Sell	-2,055	Closed	-$232K	–	480
2013 Q4	$232K	Buy	+2,055	New	+$185K	0.08%	418

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Independent Portfolio Consultants's UTHR Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its United Therapeutics (UTHR) stake by 61% in Q2 2017, selling an estimated $8.73K and leaving 45 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #760.

Independent Portfolio Consultants first reported a position in UTHR in Q4 2013 and has held it in 13 quarters since. The position peaked at $232K in Q4 2013. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Independent Portfolio Consultants held 45 shares of United Therapeutics worth $6K as of Q2 2017.
Independent Portfolio Consultants sold 70 United Therapeutics shares in Q2 2017, an estimated $8.73K.
United Therapeutics made up ﹤0.01% of Independent Portfolio Consultants's portfolio in Q2 2017, its #760 holding.
Independent Portfolio Consultants first reported a position in United Therapeutics in Q4 2013 and has held it in 13 quarters since.
Independent Portfolio Consultants's United Therapeutics position peaked at $232K in Q4 2013.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.